Notice2023-14919
Advisory Committee; National Mammography Quality Assurance Advisory Committee; Renewal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 14, 2023
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is announcing the renewal of the National Mammography Quality Assurance Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the National Mammography Quality Assurance Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the July 7, 2025, expiration date.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 134 (Friday, July 14, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 134 (Friday, July 14, 2023)]
[Notices]
[Pages 45226-45227]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-14919]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-3402]
Advisory Committee; National Mammography Quality Assurance
Advisory Committee; Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of Federal advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
renewal of the National Mammography Quality Assurance Advisory
Committee by the Commissioner of Food and Drugs (the Commissioner). The
Commissioner has determined that it is in the public interest to renew
the National Mammography Quality Assurance Advisory Committee for an
additional 2 years beyond the charter expiration date. The new charter
will be in effect until the July 7, 2025, expiration date.
DATES: Authority for the National Mammography Quality Assurance
Advisory Committee will expire on July 7, 2025, unless the Commissioner
formally determines that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT: James Swink, Office of Management,
Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5211, Silver
Spring, MD 20993-0002, 301-796-6313, email: <a href="/cdn-cgi/l/email-protection#6c260d01091f423f1b0502072c0a080d4204041f420b031a"><span class="__cf_email__" data-cfemail="89c3e8e4ecfaa7dafee0e7e2c9efede8a7e1e1faa7eee6ff">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by
the Department of Health and Human Services and by the General Services
Administration, FDA is announcing the renewal of the National
Mammography Quality Assurance Advisory Committee (the Committee). The
Committee is a non-discretionary Federal advisory committee established
to provide advice to the Commissioner.
The Commissioner is charged with the administration of the Federal
Food, Drug, and Cosmetic Act and various provisions of the Public
Health Service Act. The Mammography Quality Standards Act of 1992
amends the Public Health Service Act to establish national uniform
quality and safety
[[Page 45227]]
standards for mammography facilities. The National Mammography Quality
Assurance Advisory Committee advises the Secretary and, by delegation,
the Commissioner of Food and Drugs or designee in discharging their
responsibilities with respect to establishing a mammography facilities
certification program. The Committee shall advise the HHS Secretary and
the Commissioner or designee on:
(A) developing appropriate quality standards and regulations for
mammography facilities;
(B) developing appropriate standards and regulations for bodies
accrediting mammography facilities under this program;
(C) developing regulations with respect to sanctions;
(D) developing procedures for monitoring compliance with standards;
(E) establishing a mechanism to investigate consumer complaints;
(F) reporting new developments concerning breast imaging which
should be considered in the oversight of mammography facilities;
(G) determining whether there exists a shortage of mammography
facilities in rural and health professional shortage areas and
determining the effects of personnel on access to the services of such
facilities in such areas;
(H) determining whether there will exist a sufficient number of
medical physicists after October 1, 1999; and
(I) determining the costs and benefits of compliance with these
requirements.
The Committee shall consist of a core of 15 members, including the
Chair. Members and the Chair are selected by the Commissioner or
designee from among physicians, practitioners, and other health
professionals, whose clinical practice, research specialization, or
professional expertise includes a significant focus on mammography.
Members will be invited to serve for overlapping terms of up to 4
years. Almost all members of this committee serve as Special Government
Employees. The core of voting members shall include at least four
individuals from among national breast cancer or consumer health
organizations with expertise in mammography, and at least two
practicing physicians who provide mammography services. In addition to
the voting members, the Committee shall include two nonvoting industry
representative members who have expertise in mammography equipment. The
Committee may include one technically qualified member, selected by the
Commissioner or designee, who is identified with consumer interests.
Further information regarding the most recent charter and other
information can be found at <a href="https://www.fda.gov/advisory-committees/radiation-emitting-products/national-mammography-quality-assurance-advisory-committee">https://www.fda.gov/advisory-committees/radiation-emitting-products/national-mammography-quality-assurance-advisory-committee</a> or by contacting the Designated Federal Officer (see
FOR FURTHER INFORMATION CONTACT). In light of the fact that no change
has been made to the committee name or description of duties, no
amendment will be made to 21 CFR 14.100.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees, please visit us at <a href="http://www.fda.gov/AdvisoryCommittees/default.htm">http://www.fda.gov/AdvisoryCommittees/default.htm</a>.
Dated: July 10, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-14919 Filed 7-13-23; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 14, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.